The drug targets the same receptors as Eli Lilly's tirzepatide and reported a 2% discontinuation rate linked to mostly mild gastrointestinal side effects. Roche is currently conducting two Phase III weight-management trials and starts Phase III programs for diabetes and cardiovascular outcomes in H1 2027.
Wednesday, October 21, 2026
Story
Roche Enicepatide Cuts Weight 15.5% in Phase II Diabetes Trial
Business29 days ago
Participants on a 24 mg dose of the company's once-weekly GLP-1/GIP drug normalized blood sugar levels in 62% of cases over 48 weeks. The trial, involving patients with type 2 diabetes and obesity, showed that enicepatide reduced body weight by an average of 15.5% at its highest dosage. HbA1c levels fell 2.65 percentage points from an 8.1% baseline, with 90% of the highest-dose group reaching a treatment target of 6.5% or lower.
Looking for more context or analysis?
Tilt chat provides reliable, tailored insights, alerts, and automations.